Search our Database of Scientific Publications and Authors

I’m looking for a

    4214 results match your criteria Urticaria Chronic

    1 OF 85

    A 30-year-old woman with chronic hives, intermittent fevers, and joint pain.
    Allergy Asthma Proc 2017 May;38(3):231-235
    Chronic urticaria with concomitant systemic symptoms may be seen in several rheumatologic and autoinflammatory conditions. Although most of these conditions tend to improve with corticosteroids, symptoms often recur with dose tapering. The appearance of the rash in addition to the symptom pattern and laboratory data must be considered to differentiate potential causes. Read More

    Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
    Theranostics 2017 6;7(5):1266-1276. Epub 2017 Mar 6.
    Department of Dermatology and Allergy, Charité - Universitätsmedizin, Berlin, Germany.
    Background. Treatment with omalizumab, a humanized recombinant monoclonal anti-IgE antibody, results in clinical efficacy in patients with Chronic Spontaneous Urticaria (CSU). The mechanism of action of omalizumab in CSU has not been elucidated in detail. Read More

    New Perspectives on the Diagnosis of Allergy to Anisakis spp.
    Curr Allergy Asthma Rep 2017 May;17(5):27
    Unit of Immunology, University Hospital La Paz, Paseo de La Castellana 261, 28046, Madrid, Spain.
    Purpose Of Review: To compare the prevalence of sensitization in different countries based on specific IgE values and to evaluate the use of isolated native or recombinant allergens for diagnosis.

    Recent Findings: Isolated allergens help in the diagnosis of truly sensitized patients avoiding false positives due to cross-reactions. Their use is therefore highly recommended, especially when used as a combination of several relevant allergens. Read More

    Thyroid Autoimmunity in Patients with Chronic Urticaria.
    Med Arch 2017 Feb 5;71(1):29-31. Epub 2017 Feb 5.
    Department of Dermatology and Venereology, University Clinical Center Sarajevo, Bosnia and Herzegovina.
    Introduction: chronic urticaria (CU) is a skin disorder characterized by transient, pruritic wheals persisting for longer than 6 weeks. The etiopathogenesis of the disease is still unclear, but there is evidence that autoimmunity and endocrine dysfunction may be involved.

    Aim: the aim of this study was to determine whether chronic urticaria is statistically associated with thyroid autoimmunity. Read More

    Transcriptome analysis of severely active chronic spontaneous urticaria shows an overall immunological skin involvement.
    Allergy 2017 Apr 13. Epub 2017 Apr 13.
    Department of Dermatology, Hospital del Mar IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain.
    Background: The knowledge about chronic spontaneous urticaria (CSU) phenotypes is based on its clinical characteristics, associated comorbidities, course of the disease and its response to the available effective drugs. Genotype expression and its further correlation with CSU phenotypes are still unknown. We describe the cutaneous transcriptome of patients suffering a severely active CSU refractory to antihistamine treatment. Read More

    Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: a systematic review.
    Allergy 2017 Apr 13. Epub 2017 Apr 13.
    Charité - Universitätsmedizin Berlin, Department of Dermatology and Allergy, Berlin, Germany.
    Chronic spontaneous urticaria (CSU) patients are widely held to often have other autoimmune disorders, including autoimmune thyroid disease. Here, we systematically evaluated the literature on the prevalence of thyroid autoimmunity in CSU and vice versa. There is a strong link between CSU and elevated levels of IgG anti-thyroid autoantibodies (AAbs), with most of a large number of studies reporting rates of ≥10%. Read More

    Autologous Serum and Plasma Skin Tests in Chronic Spontaneous Urticaria: A Reappraisal.
    Indian Dermatol Online J 2017 Mar-Apr;8(2):94-99
    Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
    Aim: The objective of this study was to assess autologous serum skin test (ASST) vs autologous plasma skin test (APST) response in chronic spontaneous urticaria (CSU) patients and study the significance of intensity of positive responses in relation to clinicoepidemiological parameters.

    Materials And Methods: One hundred CSU patients and 100 age and sex-matched controls were recruited. The demographic and clinical features were recorded in all patients and routine investigations were performed. Read More

    Imatinib mesylate-induced lichenoid drug eruption.
    Cutis 2017 Mar;99(3):189-192
    Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, USA.
    Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). Since then, the number of indicated uses for imatinib has substantially increased. It is increasingly important that dermatologists recognize adverse cutaneous manifestations of imatinib and are aware of their management and outcomes to avoid unnecessarily discontinuing a potentially lifesaving medication. Read More

    Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: Review of omalizumab clinical trials.
    Ann Allergy Asthma Immunol 2017 Apr;118(4):500-504
    Department of Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania.
    Background: Adults and adolescents were included in 3 phase 3 omalizumab trials in chronic idiopathic urticaria (CIU): ASTERIA I, ASTERIA II, and GLACIAL.

    Objective: To describe the baseline clinical profile of adolescent patients with CIU enrolled in the omalizumab trials to add to the limited literature available on CIU in this population.

    Methods: Data for patient demographics, baseline clinical disease characteristics, medical history, and previous CIU medication information (not efficacy assessments) from phase 3 omalizumab trials were pooled and descriptive statistical analyses performed for adolescent (12 to <18 years old) and adult (≥18 years old) subgroups. Read More

    Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria.
    Int Arch Allergy Immunol 2017 Apr 6;172(3):161-166. Epub 2017 Apr 6.
    Allergy Department, 2nd Pediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.
    Background: Nonsedating antihistamines are the treatment of choice for chronic spontaneous urticaria (CSU), while omalizumab and immunosuppressants have also been approved as an add-on treatment. Autologous whole-blood injection (AWBI) has been used in previous studies with ambiguous results. The aim of our study was to evaluate changes in the Urticaria Activity Score (UAS7), Dermatology Life Quality Index (DLQI), and Chronic Urticaria Quality of Life (CU-Q2oL) score, and also the association of serologic markers with disease severity measures after AWBI. Read More

    The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.
    Eur J Clin Pharmacol 2017 Apr 4. Epub 2017 Apr 4.
    IBS Granada, University of Granada, CIBER of Epidemiology and Public Health (CIBERESP), Granada, Spain.
    Background: Cysteinyl leukotrienes (LTC4, LTD4, and LTE4) are pro-inflammatory mediators of the 5-lipooxygenase (5-LO) pathway, that play an important role in bronchoconstriction, but can also enhance endothelial cell permeability and myocardial contractility, and are involved in many other inflammatory conditions. In the late 1990s, leukotriene receptor antagonists (LTRAs) were introduced in therapy for asthma and later on, approved for the relief of the symptoms of allergic rhinitis, chronic obstructive pulmonary disease, and urticaria. In addition, it has been shown that LTRAs may have a potential role in preventing atherosclerosis progression. Read More

    Low-dose rituximab as an adjuvant therapy in pemphigus.
    Indian J Dermatol Venereol Leprol 2017 May-Jun;83(3):317-325
    Department of Dermatology, NHL Medical College, VS Hospital, Ahmedabad, Gujarat, India.
    Background: Pemphigus is a chronic autoimmune blistering disease where systemic steroids and immunosuppressants are the mainstay of therapy, but long-term treatment with these agents is associated with many side effects. Rituximab, a chimeric monoclonal anti-CD20 antibody, in low doses has shown efficacy as an adjuvant to reduce the dose of steroids.

    Aim: To study the clinical efficacy and safety of low-dose rituximab as an adjuvant therapy in pemphigus. Read More

    Biologic Therapy in the Treatment of Chronic Skin Disorders.
    Immunol Allergy Clin North Am 2017 May 1;37(2):315-327. Epub 2017 Mar 1.
    Department of Allergy and Clinical Immunology, Respiratory Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Electronic address:
    Understanding of the immunologic pathways involved in the pathogenesis of skin-related diseases is constantly advancing. Several biologic agents play important therapeutic roles for management of patients with chronic urticaria, atopic dermatitis, and psoriasis, particularly omalizumab for antihistamine-resistant chronic urticaria, interleukin (IL)-1 inhibitors for cryopyrin-associated periodic syndrome and Schnitzler syndrome, dupilumab for recalcitrant atopic dermatitis, and IL-17 inhibitors for psoriasis. The therapeutic utility of biologic agents for patients with immune-related dermatologic disorders is likely to expand in the future. Read More

    Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria.
    J Dermatol Sci 2017 Mar 21. Epub 2017 Mar 21.
    Novartis Pharma AG, Basel, Switzerland. Electronic address:
    Background: Many patients with chronic spontaneous/idiopathic urticaria (CSU/CIU) do not respond adequately to treatment with non-sedating H1 antihistamines (H1AH). There are limited studies on use of omalizumab as add-on therapy for treatment of CSU in an Asian population.

    Objective: The POLARIS study (NCT02329223), representing the first randomized, double-blind, placebo-controlled phase III trial of omalizumab for CSU in an Eastern Asian population, evaluated efficacy and safety of omalizumab as add-on therapy for treatment of CSU. Read More

    CRP relevance in clinical assessment of chronic spontaneous urticaria Tunisian patients.
    Cutan Ocul Toxicol 2017 Apr 25:1-6. Epub 2017 Apr 25.
    c Faculty of Pharmacy Biochemistry and Molecular Biology Laboratory, University of Monastir , Monastir , Tunisia.
    Background: Chronic spontaneous urticaria (CSU) is a common dermatological condition defined by the sudden occurrence of daily wheals and pruritus for at least six weeks. Multifactorial origin is suggested such as oxidative stress. This latter may play a double role as a trigger and remnant agent. Read More

    Soluble CD93 in Serum as a Marker of Allergic Inflammation.
    Yonsei Med J 2017 May;58(3):598-603
    Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea.
    Purpose: CD93 is receiving renewed attention as a biomarker of inflammation. We aimed to evaluate the potential for serum sCD93 to serve as a novel biomarker for allergic inflammation.

    Materials And Methods: We enrolled 348 subjects with an allergic disease [allergic rhinitis (AR), chronic spontaneous urticaria (CSU), or bronchial asthma (BA)], including 14 steroid-naïve BA patients who were serially followed-up. Read More

    Management of chronic inducible urticaria according to the guidelines: A prospective controlled study.
    J Dermatol Sci 2017 Mar 1. Epub 2017 Mar 1.
    Okmeydanı Training and Research Hospital, Department of Dermatology, Kaptanpasa Mah. Darülaceze Cad. No: 27, 34384 Okmeydanı, Şişli, Istanbul, Turkey. Electronic address:
    Background: The recommended treatment approach in chronic inducible urticarias (CIndU) is the same as that for chronic spontaneous urticaria (CSU). But there is a lack of controlled trials assessing efficacy of available treatment options.

    Objective: We aimed to evaluate the efficacy of treatment algorithm recommended by the guidelines and comparison of treatment responses in CIndU vs CSU. Read More

    Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy.
    Acta Derm Venereol 2017 Mar 17. Epub 2017 Mar 17.
    Department of Dermatology, Hospital del Mar-Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona (UAB), Passeig Marítim, 25-29, ES-08003 Barcelona, Spain.
    Although the efficacy of omalizumab has been clearly demonstrated in the treatment of chronic spontaneous urticaria (CSU), its mechanism of action, which results in improvement in CSU symptoms, is not entirely understood. This study investigated the effect of omalizumab on expression of the high-affinity IgE receptor (FcεRI) on blood basophils from patients with active CSU, and its association with the clinical response. Patients exhibiting significant clinical improvement showed a sharp reduction in the levels of basophil FcεRI after 4 weeks, which was maintained throughout the total duration of the treatment. Read More

    Chronic Idiopathic Urticaria: Systemic Complaints and Their Relationship with Disease and Immune Measures.
    J Allergy Clin Immunol Pract 2017 Mar 13. Epub 2017 Mar 13.
    Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Md. Electronic address:
    Background: Patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria sometimes report systemic complaints (SCs).

    Objective: We sought to determine the frequency and characteristics of SCs among patients with CIU, as well as the association of SCs with disease measures, basophil histamine release, and serum tryptase.

    Methods: Adult patients with CIU were recruited from a university allergy clinic. Read More

    Follicular traction urticaria.
    An Bras Dermatol 2016 Sep-Oct;91(5 suppl 1):64-65
    Okmeydani Training and Research Hospital - Istanbul, Turkey.
    Inducible urticaria is a heterogeneous subgroup of chronic urticarias caused by a wide variety of environmental stimuli, such as exercise, cold, heat, pressure, sunlight, vibration, and water. A new term, follicular traction urticaria, was suggested as an unusual form of inducible urticarias. We report a patient who was diagnosed with follicular traction urticaria. Read More

    Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria.
    J Eur Acad Dermatol Venereol 2017 Mar 16. Epub 2017 Mar 16.
    Department of Dermatology and Allergy, Allergie-Centrum Charité/ECARF, Charité - Universitätsmedizin Berlin, Berlin, Germany.
    Biomarkers useful for the evaluation and management of patients with chronic spontaneous urticaria (CSU) are not currently available. A review of various clinical and laboratory markers that have been studied to assess their value for determining the severity or predicting the evolution of disease in adult patients with CSU was carried out. A search of the medical literature on PubMed and MEDLINE including the terms urticaria, chronic urticaria, chronic idiopathic urticaria, CSU, severity, prognosis and treatment was performed. Read More

    Adult-onset Still's disease with atypical cutaneous manifestations.
    Medicine (Baltimore) 2017 Mar;96(11):e6318
    aDepartment of Rheumatology bDepartment of Dermatology, Hospital Universitario de Bellvitge-IDIBELL, Barcelona, Spain.
    The diagnosis of adult-onset Still's disease (AOSD) can be very difficult. There are no specific tests available, and diagnosis is usually based on a symptom complex and the well-described typical evanescent rash seen in the majority of patients. However, in recent years, other atypical cutaneous manifestations of AOSD have been reported. Read More

    Analysis of Disease Activity Categories in Chronic Spontaneous/Idiopathic Urticaria.
    Br J Dermatol 2017 Mar 13. Epub 2017 Mar 13.
    Cutaneous Allergy, Guy's Hospital, London, United Kingdom.
    Background: Measurement of disease activity guides treatment of chronic spontaneous urticaria (CSU). A weekly Urticaria Activity Score-here, the average of twice-daily patient assessment of itch and hives scores summed over 1 week (UAS7TD )-measures severity from 0 to 42. Insufficient evidence exists whether disease activity states, defined by categorical UAS7TD scores, correlate with other patient-reported outcomes and treatment response. Read More

    [The alpha-gal syndrome: an allergic reaction to mammalian meat secondary to a tick bite].
    Ned Tijdschr Geneeskd 2017 ;161(0):D1062
    Rijksuniversiteit Groningen/Universitair Medisch Centrum Groningen, afd. Interne Geneeskunde, onderafdeling Allergologie, Groningen.
    Here we present the case of a 68-year-old patient with alpha-gal syndrome. This is a delayed-onset allergic reaction, characteristically occurring 2-6 hours after ingestion of mammalian meat products. The reaction occurs because the patient has developed IgE antibodies to a mammalian oligosaccharide epitope, galactose-α-1,3-galactose (alpha-gal); tick bites induce this IgE antibody response. Read More

    Successful Omalizumab treatment in HIV positive patient with chronic spontaneous urticaria: a case report.
    Eur Ann Allergy Clin Immunol 2017 Mar;49(2):88-91
    Allergy and Clinical Immunology and 1st Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Milano, Italy.
    Summary: We described a case of a 56 year old homosexual HIV positive man who presented a history of CSU since one year (2012). All the allergologic, immunologic and microbiologic tests to evaluate the pathogenesis of wheals resulted negative. Therefore in June 2015 we decided to start therapy with Omalizumab while the patient kept on effective antiretroviral therapy with 310 cells/mm3 TCD4 counts and undetectable HIV viremia. Read More

    IgE, IgG1 and IgG4 response to specific allergens in sensitized subjects showing different clinical reactivity to Anisakis simplex.
    Eur Ann Allergy Clin Immunol 2017 Mar;49(2):52-58
    Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy. Phone: +39 02 9903 8470 Fax: +39 02 9903 8223 E-mail:
    Summary: Background. Anisakis simplex hypersensitive subjects may be sensitized without clinical allergy, or experience acute symptoms or chronic urticaria induced by raw fish. We studied whether the 3 subgroups differ in IgE, IgG1 or IgG4 reactivity to specific Anisakis simplex allergens. Read More

    Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study.
    J Eur Acad Dermatol Venereol 2017 Mar 10. Epub 2017 Mar 10.
    Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
    Background: Chronic urticaria (CU) is characterized by the recurrence of itchy hives and/or angioedema for more than 6 weeks. AWARE (A World-wide Antihistamine-Refractory Chronic Urticaria Patient Evaluation) is a multinational study designed to document the real-life treatment situation, burden of disease and clinical resource usage of H1-antihistamine-refractory CU patients.

    Objective: To examine baseline data from Scandinavian AWARE patients. Read More

    Levodropropizine-Induced Anaphylaxis: Case Series and Literature Review.
    Allergy Asthma Immunol Res 2017 May;9(3):278-280
    Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
    Levodropropizine is commonly used as an antitussive drug for acute and chronic cough. It is a non-opioid agent with peripheral antitussive action via the modulation of sensory neuropeptide levels in the airways. Thus, levodropropizine has a more tolerable profile than opioid antitussives. Read More

    Prevalence and Risk Factors of Urticaria With a Focus on Chronic Urticaria in Children.
    Allergy Asthma Immunol Res 2017 May;9(3):212-219
    Department of Pediatrics, Bundang CHA Medical Center, CHA University School of Medicine, Seongnam, Korea.
    Purpose: Limited data is available on the prevalence and risk factors of acute and chronic urticaria in children. Our purpose was to determine the prevalence and identify the risk factors of acute and chronic urticaria in Korean children.

    Methods: This population-based study examined 4,076 children (age 4 to 13 years) who were enrolled in the 2015 prospective Seongnam Atopy Project (SAP 2015) in Korea. Read More

    Effectiveness and safety of antihistamines up to fourfold or higher in treatment of chronic spontaneous urticaria.
    Clin Transl Allergy 2017 14;7. Epub 2017 Feb 14.
    Department of Dermatology and Allergology, University Medical Center Utrecht (G02.124), PO Box 85.500, 3508 GA Utrecht, The Netherlands.
    Background: Treatment with second-generation antihistamines is recommended in patients with chronic spontaneous urticaria (CSU). Some patients remain unresponsive even after up-dosing up to fourfold. Many third line treatment options have limited availability and/or give rise to significant side effects. Read More

    How to Diagnose and Classify Tattoo Complications in the Clinic: A System of Distinctive Patterns.
    Curr Probl Dermatol 2017 10;52:58-73. Epub 2017 Mar 10.
    The 'Tattoo Clinic', Department of Dermatology, Bispebjerg University Hospital, Copenhagen, Denmark.
    Tattoo complications represent a broad spectrum of clinical entities and disease mechanisms. Infections are known, but chronic inflammatory reactions have hitherto been inconsistently reported and given many interpretations and terms. A clinical classification system of distinct patterns with emphasis on inflammatory tattoo reactions is introduced. Read More

    Analysis of the association of chronic spontaneous urticaria with interlekin-4, -10, transforming growth factor-β1, interferon-γ, interleukin-17A and -23 by autologous serum skin test.
    Postepy Dermatol Alergol 2017 Feb 7;34(1):70-76. Epub 2017 Feb 7.
    Department of Public Health, Faculty of Medicine, Celal Bayar University, Manisa, Turkey.
    Aim: To contribute to the understanding of the pathogenesis of chronic spontaneous urticaria (CSU) by identifying its relationship with autoimmunity and cytokines using the autologous serum skin test (ASST) and peripheral blood mononuclear cell culture (PBMC) method.

    Material And Methods: Interleukins (IL)-4, IL-10, transforming growth factor (TGF-β1), interferon (IFN)-γ, IL-17A, and IL-23 levels in cell supernatants obtained by the PBMC method were measured using ELISA. Disease activity was assessed by determining the urticaria activity score (UAS). Read More

    [Association between C reactive protein and clinical characteristics in patients with chronic spontaneous urticaria].
    Zhong Nan Da Xue Xue Bao Yi Xue Ban 2017 Feb;42(2):168-172
    Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China.
    Objective: To explore the association among C reactive protein (CRP) level, disease severity and non-sedating antihistamine drug efficacy in patients with chronic spontaneous urticaria.
 Methods: A total of 605 patients with chronic spontaneous urticaria from August 2013 to March 2015, diagnosed by dermatologist of Xiangya Hospital according to the guideline, were enrolled in present study. The patients were divided into two groups according to the weekly urticaria activity score (UAS): a response group (more than 50% reduction) and a nonresponse group (less than 50% reduction). Read More

    Effectiveness of omalizumab in a case of urticarial vasculitis.
    Clin Exp Dermatol 2017 Mar 1. Epub 2017 Mar 1.
    Department of Dermatology, Hospital Clinico Universitario San Carlos, Madrid, Spain.
    Urticarial vasculitis (UV) is a mainly leucocytoclastic vasculitis with urticarial plaques. Treating these patients is challenging as the available treatments have poor efficacy. Oral corticosteroids are considered the first-line treatment, but H1 antihistamines, dapsone, colchicine, antimalarials, ciclosporin and antileucotrienes have all been tried also. Read More

    The persistence of chronic spontaneous urticaria in childhood is associated with the urticaria activity score.
    Allergy Asthma Proc 2017 03;38(2):136-142
    Background: There is little information regarding the etiology and natural course of chronic spontaneous urticaria (CSU) in childhood.

    Objective: To investigate the etiology, prognosis, and the factors associated with the prognosis of CSU in children.

    Method: Data from children with CSU who had been diagnosed between 1992 and 2015 were analyzed. Read More

    [Diagnostic and Therapeutic Approach of Chronic Spontaneous Urticaria: Recommendations in Portugal].
    Acta Med Port 2016 Nov 30;29(11):763-781. Epub 2016 Nov 30.
    Serviço de Dermatologia. Centro Hospitalar e Universitário de Coimbra. Coimbra. Portugal; Clínica de Dermatologia. Faculdade de Medicina. Universidade de Coimbra. Coimbra. Portugal.
    Chronic spontaneous urticaria is a complex disorder, of unclear etiology, easily diagnosed although often difficult to treat. It has a significant impact on the patients' quality of life and results in high direct and indirect costs. The diagnosis of chronic spontaneous urticaria is mainly clinical and a limited number of tests is recommended for differential diagnosis and/or for the investigation/exclusion of possible causes. Read More

    Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature.
    Pharmacotherapy 2017 Apr 23;37(4):464-480. Epub 2017 Mar 23.
    Institute of Applied Sciences and Intelligent Systems "Eduardo Caianiello" (ISASI), National Research Council of Italy (CNR), Messina, Italy.
    Omalizumab is recombinant humanized monoclonal antibody to immunoglobulin E. Guidelines for the treatment of chronic idiopathic urticaria (also known as chronic spontaneous urticaria) recommend the use of omalizumab as third-line therapy in addition to high doses of histamine receptor type 1 (H1 ) antihistamines when they are unsuccessful as first- and second-line therapy. We performed a systematic review of the literature to identify studies that evaluated the efficacy of omalizumab for the treatment of chronic idiopathic urticaria, in both controlled and real-world settings, to assess its potential role as a preferred therapy. Read More

    Management of Chronic Spontaneous Urticaria in Routine Clinical Practice Following the EAACI/GA(2)LEN/EDF/WAO Guidelines.
    Actas Dermosifiliogr 2017 Feb 20. Epub 2017 Feb 20.
    Servicio de Dermatología, Hospital General Universitario de Alicante, Alicante, España.
    Introduction: Chronic spontaneous urticaria is a prevalent and difficult-to-treat condition that has a very negative impact on patient quality of life.

    Objective: To describe the epidemiological and clinical characteristics of patients presenting with chronic spontaneous urticaria and the response to treatment administered according to the EAACI/GA(2)LEN/EDF/WAO consensus guideline.

    Material And Method: Descriptive cross-sectional study of all the patients with chronic spontaneous urticaria who consulted a skin allergy unit in the dermatology department of a tertiary hospital in Spain between July 2011 and July 2015. Read More

    D-Dimer Plasma Levels Parallel the Clinical Response to Omalizumab in Patients with Severe Chronic Spontaneous Urticaria.
    Int Arch Allergy Immunol 2017 21;172(1):40-44. Epub 2017 Feb 21.
    Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy.
    Omalizumab is very effective in the majority of patients with severe chronic spontaneous urticaria (CSU), but its mechanism of action is still unclear. In CSU the coagulation cascade is activated with an intensity that parallels the disease severity, and elevated plasma D-dimer levels are associated with a poor response to both antihistamines and cyclosporin. We measured D-dimer plasma levels before and after the first administration of omalizumab in 32 patients with severe CSU. Read More

    Synergistic Actions of Histamine-Releasing Factor and Histamine Releasing Factor-Reactive IgE in Chronic Urticaria.
    Int Arch Allergy Immunol 2017 21;172(1):27-32. Epub 2017 Feb 21.
    Department of Dermatology, Daping Hospital, Third Military Medical University, Chongqing, China.
    The etiology of chronic urticaria (CU) remains elusive. Histamine-releasing factor (HRF) is reported to have a proinflammatory role in asthma and immediate hypersensitivity of the skin. The aim of this study was to examine the role of HRF in the pathogenesis of CU. Read More

    Elevated Nitrosative Stress in Children with Chronic Spontaneous Urticaria.
    Int Arch Allergy Immunol 2017 21;172(1):33-39. Epub 2017 Feb 21.
    Departments of Pediatric Allergy and Immunology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
    Background: Chronic spontaneous urticaria (CSU) is an idiopathic condition that seriously affects quality of life. It is well known that oxidative stress and nitrosative stress (NS) are generally involved in many chronic inflammatory diseases. This study aimed to evaluate the possible role of NS in the pathogenesis of CSU. Read More

    Food Protein-Induced Enterocolitis Syndrome.
    J Investig Allergol Clin Immunol 2017 ;27(1):1-18
    Unidade de Alergia e Imunologia do Instituto da Criança, HC Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
    Food protein-induced enterocolitis syndrome (FPIES) is a non-IgE-, cell-mediated food allergy of unknown prevalence and pathophysiology. Onset is typically during the first year of life; seafood-induced FPIES may start in adulthood. Acute FPIES manifests within 1-4 hours after ingestion with repetitive emesis, pallor, and lethargy progressing to dehydration and hypovolemic shock in 15% of cases. Read More

    Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease).
    Circ Cardiovasc Interv 2017 Feb;10(2)
    From the Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo, Italy (R.R., A.I., G.M., M.S.); Division of Cardiology, A.O.U San Luigi Gonzaga, Orbassano, Torino, Italy (R.P., M.B.); IRCCS Fondazione Policlinico S. Matteo, Pavia, Italy (S.L.); Divisione di Cardiologia, Ospedale Carlo Poma, Mantova, Italy (C.L.); Cardiologia 1 Emodinamica, Dipartimento Cardiovascolare, ASST Niguarda Grande Ospedale Metropolitano, Milano, Italy (I.B., P.C.); U.O. Emodinamica, Ospedale Sandro Pertini, Roma, Italy (S.R.); Università degli Studi di Pavia, Italy (C.D.); Unità operativa di Cardiologia, Humanitas Mater Domini, Castellanza (Varese), Italy (A.A.); Cardio-Thoracic-Vascular Department, Ferrarotto Hospital, University of Catania, Italy (D.C.); and Division of Cardiology, University of Florida College of Medicine, Jacksonville (D.J.A.).
    Background: There are limited data on aspirin (ASA) desensitization for patients with coronary artery disease. The aim of the present study was to assess the safety and efficacy of a standard rapid desensitization protocol in patients with ASA sensitivity undergoing coronary angiography.

    Methods And Results: This is a prospective, multicenter, observational study including 7 Italian centers including patients with a history of ASA sensitivity undergoing coronary angiography with intent to undergo percutaneous coronary intervention. Read More

    1 OF 85